Frontier Biotechnologies (SHSE:688221) - Stock Price, News & Analysis

688221 Stock Overview

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health.

About the company

688221 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 15.7% per year over past 5 years

Frontier Biotechnologies Inc. Competitors

Lifecome BiochemistryLtd

SZSE:002868

CN¥2.4b

Xinjiang Tianshan Animal Husbandry Bio-engineering

SZSE:300313

CN¥2.1b

Landfar Bio-medicine

SZSE:000504

CN¥2.6b

HOB Biotech GroupLtd

SHSE:688656

CN¥1.6b

Price History & Performance

Summary of all time highs, changes and price drops for Frontier Biotechnologies
Historical stock prices
Current Share Price	CN¥6.58
52 Week High	CN¥13.16
52 Week Low	CN¥5.09
Beta	0.92
1 Month Change	-6.00%
3 Month Change	1.08%
1 Year Change	-45.21%
3 Year Change	-54.40%
5 Year Change	n/a
Change since IPO	-78.00%

Recent updates

Shareholder Returns

	688221	CN Biotechs	CN Market
7D	7.9%	4.3%	2.9%
1Y	-45.2%	-21.4%	-13.2%

Return vs Industry: 688221 underperformed the CN Biotechs industry which returned -21.4% over the past year.

Return vs Market: 688221 underperformed the CN Market which returned -13.2% over the past year.

Price Volatility

Is 688221's price volatile compared to industry and market?
688221 volatility
688221 Average Weekly Movement	9.5%
Biotechs Industry Average Movement	7.8%
Market Average Movement	8.5%
10% most volatile stocks in CN Market	12.5%
10% least volatile stocks in CN Market	5.1%

Stable Share Price: 688221 has not had significant price volatility in the past 3 months.

Volatility Over Time: 688221's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	395	C. J. Wang	www.frontierbiotech.com

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS.

Frontier Biotechnologies Inc. Fundamentals Summary

How do Frontier Biotechnologies's earnings and revenue compare to its market cap?
688221 fundamental statistics
Market cap	CN¥2.46b
Earnings (TTM)	-CN¥308.96m
Revenue (TTM)	CN¥126.99m

19.4x

P/S Ratio

-8.0x

P/E Ratio

Is 688221 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688221 income statement (TTM)
Revenue	CN¥126.99m
Cost of Revenue	CN¥85.34m
Gross Profit	CN¥41.64m
Other Expenses	CN¥350.60m
Earnings	-CN¥308.96m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.82
Gross Margin	32.79%
Net Profit Margin	-243.30%
Debt/Equity Ratio	30.7%

How did 688221 perform over the long term?

See historical performance and comparison

688221 Stock Overview

Rewards

Risk Analysis

Frontier Biotechnologies Inc. Competitors

SZSE:002868

CN¥2.4b

SZSE:300313

CN¥2.1b

SZSE:000504

CN¥2.6b

SHSE:688656

CN¥1.6b

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Recent updates

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

Shareholder Returns

Price Volatility

About the Company

Frontier Biotechnologies Inc. Fundamentals Summary

19.4x

-8.0x

Earnings & Revenue